Carl M. J. Kirkpatrick

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution

Jason A. Roberts, Carl M. J. Kirkpatrick, Michael S. Roberts et al. · Journal of Antimicrobial Chemotherapy · 2009 · 348 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

Veronique Chachay, Graeme A. Macdonald, Jennifer Martin et al. · Clinical Gastroenterology and Hepatology · 2014 · 284 citations · Full text

Medicine, Biochemistry, Pharmacotherapy +9

Dosing in Obesity: A Simple Solution to a Big Problem

Phey Yen Han, Stephen B. Duffull, Carl M. J. Kirkpatrick et al. · Clinical Pharmacology & Therapeutics · 2007 · 242 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis

Jason A. Roberts, Carl M. J. Kirkpatrick, Michael S. Roberts et al. · International Journal of Antimicrobial Agents · 2009 · 195 citations

Medicine, Pharmacokinetics, Pharmacology +16

Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients

Jason A. Roberts, Carl M. J. Kirkpatrick, Jeffrey Lipman · Journal of Antimicrobial Chemotherapy · 2010 · 149 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17